Nonsurgical treatment options for Basal cell carcinoma
- PMID: 21274437
- PMCID: PMC3025364
- DOI: 10.1155/2011/571734
Nonsurgical treatment options for Basal cell carcinoma
Abstract
Basal cell carcinoma (BCC) remains the most common form of nonmelanoma skin cancer (NMSC) in Caucasians, with perhaps as many as 2 million new cases expected to occur in the United States in 2010. Many treatment options, including surgical interventions and nonsurgical alternatives, have been utilized to treat BCC. In this paper, two non-surgical options, imiquimod therapy and photodynamic therapy (PDT), will be discussed. Both modalities have demonstrated acceptable disease control rates, cosmetically superior outcomes, and short-term cost-effectiveness. Further studies evaluating long-term cure rates and long-term cost effectiveness of imiquimod therapy and PDT are needed.
References
-
- Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA: A Cancer Journal for Clinicians. 2010;60(5):277–300. - PubMed
-
- Chen TM, Rosen T, Orengo I. Treatment of a large superficial basal cell carcinoma with 5% imiquimod: a case report and review of the literature. Dermatologic Surgery. 2002;28(4):344–346. - PubMed
-
- Tran H, Chen K, Shumack S. Epidemiology and aetiology of basal cell carcinoma. British Journal of Dermatology, Supplement. 2003;149(66):50–52. - PubMed
-
- Lear W, Dahlke E, Murray CA. Basal cell carcinoma: review of epidemiology, pathogenesis, and associated risk factors. Journal of Cutaneous Medicine and Surgery. 2007;11(1):19–30. - PubMed
-
- Spencer JM, Tannenbaum A, Sloan L, Amonette RA. Does inflammation contribute to the eradication of basal cell carcinoma following curettage and electrodesiccation? Dermatologic Surgery. 1997;23(8):625–631. - PubMed
LinkOut - more resources
Full Text Sources
